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Background
Cardiac resynchronisation therapy (CRT) reduces major 
adverse cardiac events (MACE), and improves exercise 
capacity and functional class, in drug refractory heart 
failure patients (NYHA ≥ II) with ventricular conduction 
delay [1–3]. However, the degree of CRT response varies 
widely and ranges from MACE rates similar to heart failure 
patients without CRT to rates comparable with a matched 
sample from the general population [4, 5]. In daily clinical 
practice, degree of CRT response is assessed 6 months after 
CRT implantation using echocardiographic change (∆) of 
left ventricular end-systolic volume (LVESV) [6]. However, 
whether ∆LVESV is the most appropriate surrogate marker 
has not been extensively investigated. Furthermore, due to 
differences in underlying disease, response measures might 
not be equally appropriate for patients with non-ischaemic 
and ischaemic cardiomyopathy.
Two basic criteria need to be fulfilled for a variable to be 
a suitable surrogate marker: (1) A relation has to be dem-
onstrated between the change of the surrogate marker over 
time (e.g. LVESV decrease) and the true endpoint (MACE), 
and (2) a pathophysiological foundation must be known to 
consider the surrogate marker as a main determinant of the 
true endpoint [7]. LVESV declines after CRT due to reverse 
remodelling and has been demonstrated to correlate with 
a favourable prognosis [8, 9]. Besides change in LV vol-
ume, changes in parameters indicating LV systolic function, 
mechanical dyssynchrony, cardiopulmonary condition and 
biomarkers of overall cardiovascular function are potential 
surrogate markers for CRT response [10–17].
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Background Change in left ventricular end-systolic volume 
(∆LVESV) is the most frequently used surrogate marker in 
measuring response to cardiac resynchronisation therapy 
(CRT). We investigated whether ∆LVESV is the best mea-
sure to discriminate between a favourable and unfavourable 
outcome and whether this is equally applicable to non-isch-
aemic and ischaemic cardiomyopathy.
Methods 205 CRT patients (age 65 ± 12 years, 69 % men) 
were included. At baseline and 6 months echocardiographic 
studies, exercise testing and laboratory measurements were 
performed. CRT response was assessed by: ∆LVESV, ∆LV 
ejection fraction (LVEF), ∆ interventricular mechanical de-
lay, ∆VO2 peak, ∆VE/VCO2, ∆BNP, ∆creatinine, ∆NYHA, 
and ∆QRS. These were correlated to the occurrence of major 
adverse cardiac events (MACE) between 6 and 24 months.
Results MACE occurred in 19 % of the patients (non-isch-
aemic: 13 %, ischaemic: 24 %). ∆LVESV remained the only 
surrogate marker for CRT response for the total population 
and patients with non-ischaemic cardiomyopathy, showing 
areas under the curve (AUC) of 0.69 and 0.850, respective-
ly. For ischaemic cardiomyopathy, ∆BNP was the best sur-
rogate marker showing an AUC of 0.66.
Conclusion ∆LVESV is an excellent surrogate marker 
measuring CRT response concerning long-term outcome 
for non-ischaemic cardiomyopathy. ∆LVESV is not suitable 
for ischaemic cardiomyopathy in which measuring CRT re-
sponse remains difficult.
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In this study we investigated (1) several surrogate mark-
ers for CRT response, and (2) whether these surrogate 
markers were equally applicable for non-ischaemic and 
ischaemic cardiomyopathy.
Methods
Study design and cohort
This was a retrospective study in which we included 205 
consecutive patients who received a CRT device (200 
received a CRT defibrillator and four a CRT pacemaker) in 
the University Medical Center Utrecht (UMCU) between 
August 2005 and August 2011, with prospectively planned 
echocardiographic studies, cardiopulmonary exercise test-
ing and laboratory evaluation available before implantation. 
It was recommended not to change device settings during 
the first 6 months. Configurations were only adjusted by 
exception, during regular check-up at 2 months. Thereafter, 
until the six-month point of assessment, pacing configura-
tions remained unchanged.
Six months after device implantation, evaluation of the 
echocardiographic studies, cardiopulmonary exercise test-
ing and laboratory tests was repeated. To determine the 
best surrogate marker for CRT response, the correlation 
between all potential surrogate CRT response measure-
ments and MACE occurring between 6 and 24 months was 
assessed. We did not include MACE occurring before our 
six-month evaluation point, as therapy effect was quantified 
at 6 months in order to gather prognostic information for 
the period afterwards, not the preceding period. In addition, 
the effect of CRT might not yet be optimal in the preced-
ing period, which was another reason why we chose not to 
include MACE occurring in the first 6 months to correlate to 
surrogate response measurements. The study was conducted 
in accordance with the Declaration of Helsinki.
Response to CRT was assessed 6 months after device 
implantation by (1) ∆LVESV (%), (2) ∆left ventricular 
ejection fraction (LVEF; absolute %), (3) ∆interventricu-
lar mechanical delay (IVMD; ms), (4) ∆VO2 peak (ml/kg/
min), (5) ∆ percentage of predicted VO2 peak (absolute %), 
(6) ∆VE/VCO2 slope, (7) ∆brain natriuretic peptide (BNP; 
pmol/L), (8) ∆creatinine (µmol/L), ∆NYHA, and ∆QRS 
duration.
Echocardiography
Data were acquired using Philips IE 33 (Philips Medi-
cal Systems, Andover, Massachusetts, USA) or Vivid 7 
(General Electric, Milwaukee, USA) ultrasound machines. 
Echocardiographic parameters were assessed using Xcelera 
software (R3.3L1). Volumes and ejection fraction were 
assessed by Simpsons’ biplane method in accordance with 
the guidelines of the American Society of Echocardiogra-
phy (ASE) and European Association of Echocardiography 
(EAE) [10].
Doppler flows over the pulmonary and aortic valve were 
recorded and time from Q to onset of flow was assessed for 
both valves. IVMD was defined as the time span between 
opening of the aortic valve and the pulmonary valve [6]. 
Measurements were performed on three separate beats, or 
five beats in case of irregular rhythms.
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing on the bicycle ergometer 
started with unloaded cycling for 2 min after which a pro-
tocol of stepwise incremental exercise was applied, starting 
at 25 W with increments of 5, 10 or 15 W every minute 
depending on the estimated maximum workload. Rotation 
speed was kept around 60 per minute. Prior to testing, gas 
and flow sensors were calibrated utilising gases with estab-
lished concentrations of O2 and CO2.
Ventilation (VE) (L/min), peak oxygen consumption 
(VO2) (mL/kg/min), and carbon dioxide production (VCO2) 
(L/min) were measured for each patient throughout the 
exercise on a breath-to-breath basis. VO2 peak and VE/
VCO2 slope were assessed. Data for the VE/VCO2 slope 
were collected throughout the exercise, with exclusion of 
the unloaded cycling and recovery period.
VO2 peak is the level of O2 consumption during maxi-
mum effort and averaged over a 30-second period [11]. The 
VE/VCO2 slope provides a measure of CO2 exchange effi-
ciency by assessing required ventilation for CO2 elimination 
[11].
Long-term follow-up and assessment of major adverse 
cardiac events
MACE was defined as: hospital admission for heart failure, 
sustained ventricular tachycardia (VT) (VT lasting > 30 s or 
a VT beneath the monitoring zone leading to hospitalisa-
tion), ventricular fibrillation (VF), receiving a left ventricu-
lar assist device (LVAD), undergoing heart transplantation, 
death due to heart failure and appropriate implantable car-
dioverter defibrillator (ICD) shocks (due to VT or VF). Mul-
ticentre studies proved a CRT defibrillator was beneficial 
over a CRT pacemaker device concerning long-term sur-
vival, indicating that the shock function of the defibrillator 
prevents MACE in a heart failure population and therefore 
an appropriate shock was considered as an adverse cardiac 
event [12].
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Long-term follow-up and major adverse cardiac events
Six patients died before six-month follow-up, one patient had 
undergone a heart transplant and one received an LV assist 
device; these patients were not included for further analy-
ses. Of the remaining 197 patients, four patients were lost to 
follow-up, two died of a non-cardiac cause and one died of 
an unknown cause (Fig. 1). Between 6 and 24 months 19 % 
(36/190) experienced at least one MACE. Twenty patients 
had a hospital admission due to heart failure, nine had ven-
tricular arrhythmias, and seven died due to heart failure. Of 
Statistical analyses
Statistical analysis was performed using SPSS version 20.0 
(SPSS Inc., Chicago, Illinois). Continuous variables are pre-
sented as mean with standard deviation (SD) when normally 
distributed (mean ± SD) and as median with interquartile 
range (IQR) in case of non-normal distribution (median 
(IQR)). Distributions were checked using Q-Q plots. Cate-
gorical variables are presented as numbers and percentages.
Surrogate markers of CRT response were assessed for 
the total population, and the ischaemic and non-ischaemic 
subpopulations. Data were compared with a T-test or Mann-
Whitney U test in case of non-normal distribution. A p-value 
of < 0.05 was considered statistically significant. Surrogate 
markers demonstrating a significant difference between 
patients with and without MACE were subsequently 
tested using univariable and multivariable Cox backward 
logistic regression analyses. Areas under the receiver-
operating curve (AUC) were assessed with respect to the 
occurrence of MACE. Subsequently, Cox regression mul-
tivariable analyses were performed to evaluate the associa-
tion between significant surrogate markers and time to first 
MACE. These analyses were performed for the total popu-
lation, ischaemic and non-ischaemic subpopulations. Multi-
collinearity amongst variables was checked using variance 
inflation factors, and a value of > 5 was considered evidence 
of multicollinearity. Furthermore, the relation between sur-
rogate markers of CRT response and MACE was calculated 
by the Kaplan-Meier method and compared by means of the 




Baseline characteristics are listed in Table 1. Mean age 
65 ± 12 years, 69 % (n = 142) male, 52 % (n = 106) with isch-
aemic cardiomyopathy. At baseline, LVESV was 180 (87) 
mL, LVEF 22 ± 7 %, and IVMD 46 ± 28 ms. Baseline VO2 
peak was 14 ± 4 ml/kg/min, predicted VO2 peak 61 ± 19 % 
and VE/VCO2 slope 38 (15). Baseline BNP levels were 112 
(172) pmol/L and creatinine levels were 112 (52) µmol/L.
Six-month results
Six-month follow-up values are listed in Table 1. At six-
month follow-up LVESV was 133 (95) ml, LVEF 29 ± 10 %, 
and IVMD was 15 ± 28 ms. VO2 peak was 15 ± 5 ml/kg/min, 
predicted VO2 peak 67 ± 23 % and VE/VCO2 slope 34 (11). 
BNP levels were 71 (107) pmol/L and creatinine levels were 
115 (53) µmol/L.




FU (n = 197)
P-value
Clinical
Age, mean ± SD (years) 64.8 ± 12.4 –
Male gender (%) 142 (69) –
Ischaemic cardiomyopathy (%) 106 (52 %) –
NYHA I (%) 1 (0.5) 16 (8.3) 0.001
NYHA II (%) 26 (12.7) 104 (53.6) 0.171
NYHA III (%) 167 (81.5) 71 (36.6) 0.062
NYHA IV (%) 11 (5.3) 3 (1.5) < 0.001
ECG
QRS duration, mean ± SD, ms 166 ± 24 153 ± 24 < 0.001




Right bundle branch block (%) 1 (0.5) –
QRS < 120 ms (%) 1 (0.5) –
Right ventricular pacing (%) 23 (11) –
Echocardiography
LVESV, median (IQR), ml 180 (87) 133 (95) < 0.001
LVEDV, median (IQR), ml 230 (92) 182 (115) < 0.001
LVEF, mean ± SD (%) 21.6 ± 6.8 28.6 ± 10.4 < 0.001
IVMD, mean ± SD (ms) 46 ± 28 15 ± 28 < 0.001
Exercise test
Peak VO2, mean ± SD (ml/kg/
min)
14.0 ± 4.2 15.4 ± 4.8 < 0.001
Percentage of predicted peak 
VO2, mean ± SD (%)
61.1 ± 18.8 67.4 ± 23.2 < 0.001
VE/VCO2, median (IQR) 38 (15) 34 (11) < 0.001
Laboratory tests
BNP, median (IQR), pmol/L 112 (172) 71 (107) < 0.001
Creatinine, median (IQR), 
µmol/L
112 (52) 115 (53) 0.002
Medication
Beta-blocker (%) 157 (78) –
ACE-inhibitor (%) 152 (76) –
Diuretics (%) 180 (90) –
BNP brain natriuretic peptide, FU follow-up, IVMD interventricular 
mechanical delay, LVEF left ventricular ejection fraction, LVEDV 
left ventricular end-diastolic volume, LVESV left ventricular end-
systolic volume, NYHA New York Heart Association, VO2 oxygen 
consumption, VE/VCO2 CO2 exchange efficiency.
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independent surrogate marker for CRT response (Table 5). 
Discriminative power was moderate with AUC 0.66.
Concerning Fig. 2, a 15 % cut-off for ∆LVESV was cho-
sen, as this is the most often used cut-off value to discrimi-
nate between responders and non-responders [6, 9].
Discussion
For the total population, ∆LVESV was the most reliable sur-
rogate marker for CRT response. Especially in the non-isch-
aemic cardiomyopathy population, this parameter showed 
excellent performance for discriminating between favour-
able and unfavourable long-term outcome. However, we 
demonstrated that ∆LVESV is a poor surrogate marker for 
CRT response in patients with ischaemic cardiomyopathy. 
In this group of patients ∆LVESV was unable to indicate 
which patients had a favourable and which had an unfa-
vourable long-term outcome. These findings are of utmost 
importance as ∆LVESV is frequently chosen as outcome 
measure to assess response to CRT treatment regardless of 
aetiology [6, 13].
the ischaemic patients 24 % (n = 24) experienced a MACE 
versus 13 % (n = 12) of non-ischaemic patients (p = 0.061).
Assessment of CRT response
∆LVESV, ∆LVEF, and ∆BNP differed significantly between 
patients with and without MACE in the total population 
(Table 2). After multivariable analyses, LVESV remained 
the only surrogate marker for CRT response significantly 
correlated to the occurrence of MACE. Discriminative 
performance of this surrogate marker was moderate: AUC 
= 0.69 (Table 3 and Fig. 2).
Associations between surrogate response markers and 
MACE differed among heart failure aetiologies (Table 3, 
Table 4 and 5). In the non-ischaemic cardiomyopathy popu-
lation results were in concordance with the total population 
as ∆LVESV remained the only surrogate marker for CRT 
response (Table 4). Discriminative power of ∆LVESV was 
high in this subpopulation: AUC = 0.85 (Fig. 1 and Fig. 3a).
In the ischaemic cardiomyopathy population no signifi-
cant correlation was found between ∆LVESV and the occur-
rence of MACE (Fig. 3b). In this group ∆BNP was the only 
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Figure 1 Flow chart of inclusion. 
CRT therapy between 2005–2011 
and prospectively planned 
baseline and 6 months CPX and 
echocardiography. CRT cardiac 
resynchronization therapy, CPX 
cardiopulmonary exercise test-
ing, LVAD left ventricular assist 
device
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by CRT as both groups showed only minor changes in cre-
atinine between baseline and 6 months. This is in line with 
a recent study [20]. Moreover, when stratified according to 
baseline renal function, patients demonstrating either an 
improvement or decline in renal function occurred for all 
disease stages and changes were therefore unpredictable 
[20]. Consequently, changes in renal function can probably 
not discriminate between favourable and unfavourable clin-
ical outcome.
Surrogate markers in ischaemic cardiomyopathy
A remarkable finding was that ∆LVESV in ischaemic car-
diomyopathy could not distinguish between patients who 
remained free of MACE during follow-up. Although ∆BNP 
was the best surrogate marker in this subpopulation, it was 
unsuitable for good discrimination. This implicates that 
ischaemic cardiomyopathy is influenced by other factors 
when it comes to long-term outcome.
Although both aetiologies are characterised by reduced 
contractility and global dilation, the disease substrate differs 
greatly. In ischaemic cardiomyopathy, coronary artery dis-
ease is the pathophysiological substrate and a high variety 
exists concerning the extent of disease, affecting prognosis, 
and making this a very heterogeneous group [21].
Furthermore, it has been demonstrated that scar tissue is 
a more important determinant of long-term outcome in isch-
aemic cardiomyopathy than contractile reserve [22]. This 
is also confirmed by the current study. As BNP is mainly 
produced by cardiomyocytes [23], it could be hypothesised 
that BNP change is only possible in patients with significant 
amounts of myocytes left, and consequently less scar tis-
sue. Also, presence of myocardial scar in the pacing region 
Surrogate markers in non-ischaemic cardiomyopathy
For non-ischaemic cardiomyopathy, ∆LVESV was the best 
surrogate marker in our study. The importance of change in 
LV volume during CRT over other surrogate markers has 
been demonstrated previously and seems to be in concor-
dance with our data [8, 14]. ∆LVESV was independent of 
change in LV systolic function, cardiopulmonary condition, 
mechanical dyssynchrony and cardiovascular biomarkers.
The clinical course of heart failure is determined by car-
diac remodelling [15]. A decrease in LVESV implies reverse 
remodelling because it reflects both structural (reverse) 
remodelling and increased fibre shortening. LVEF, as a 
parameter for LV systolic function, seems less suitable as 
surrogate marker, probably because it is more dependent on 
LV end-diastolic volume and heart rate [15].
A change of mechanical dyssynchrony was not an appro-
priate surrogate outcome marker either. Mechanical dyssyn-
chrony is not obligatory to be eligible for CRT implantation 
[16, 17]. Consequently, IVMD at baseline, and its reduc-
tion, showed a wide distribution in our study cohort, making 
∆IVMD an unsuitable surrogate marker.
Cardiopulmonary exercise testing parameters may take 
longer to improve than 6 months. It has been demonstrated 
in heart failure patients that during a training programme 
time to reach maximum improvement varied between 16 
and 26 weeks [18]. This process probably takes even longer 
without training, when it is solely influenced by CRT.
Also, neither ∆BNP nor ∆creatinine could identify those 
with a favourable or unfavourable long-term outcome in 
the non-ischaemic cardiomyopathy group. ∆BNP may not 
be reliable due to a wide distribution and high day-to-day 
variability [19]. Renal function does not seem to be affected 
Table 2 Comparison of changes in echocardiographic, cardiopulmo-
nary, and laboratory parameters between patients with and without a 
MACE





∆ LVESV (%) − 9.5 ± 18.7 − 23.5 ± 23.0 < 0.001
∆ LVEF (absolute %) 3.5 ± 6.2 8.2 ± 9.0 < 0.001
∆ IVMD (ms) − 29 ± 35 − 34 ± 32 0.422
∆ QRS duration (ms) 4.0 ± 28.4 16.4 ± 26.3 0.022
∆ Peak VO2 (ml/kg/min) 0.8 ± 3.0 1.1 ± 3.1 0.684
∆ Predicted peak VO2 (absolute %) 5.7 ± 14.7 6.0 ± 14.8 0.930
∆ VE/VCO2 slope − 2 (17) − 4 (9) 0.674
∆ BNP (pmol/L) 14.5 (125) − 21.5 (106) 0.019
∆ Creatinine (µmol/L) 0.5 (23) − 4.8 (22) 0.375
NYHA improvement (%) 12 (38) 94 (63 %) 0.009
∆ indicates a change, BNP brain natriuretic peptide, ICM ischaemic 
cardiomyopathy, IVMD interventricular mechanical delay, LVEF left 
ventricular ejection fraction, LVESV left ventricular end-systolic volume, 
MACE major adverse cardiac events, NYHA New York Heart Association, 
NICM non-ischaemic cardiomyopathy, VO2 oxygen consumption, VE/VCO2 
CO2 exchange efficiency.
Table 3 Multivariable Cox regression concerning surrogate endpoints 



















∆ BNP (pmol/L) – – 0.993 
(0.988–0.998)
∆ NYHA (class) – – –
∆ indicates a change, BNP brain natriuretic peptide, ICM ischaemic 
cardiomyopathy, IVMD interventricular mechanical delay, LVEF 
left ventricular ejection fraction, LVESV left ventricular end-systolic 
volume, MACE major adverse cardiac events, NYHA New York Heart 
Association, NICM non-ischaemic cardiomyopathy, VO2 oxygen 
consumption, VE/VCO2 CO2 exchange efficiency.
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before CRT implantation. Importantly, these results do not 
imply that CRT is not beneficial for patients with ischaemic 
cardiomyopathy.
Prediction of MACE
Although the present study searched for the best surro-
gate markers for CRT response through a correlation with 
was another important determinant of long-term outcome 
in patients with ischaemic cardiomyopathy eligible for CRT 
[24].
In addition, in about 25 % of patients disease extends 
beyond the coronary arteries and also affects the brain and 
peripheral tissues, which may affect prognosis independent 
of the amount of cardiac remodelling [25]. Therefore, it 
might be important to assess overall atherosclerotic status 
Table 4 Comparison of changes in echocardiographic, cardiopulmo-
nary, and laboratory parameters between patients with non-ischaemic 








∆ LVESV (%) − 2.4 ± 11.5 − 30.0 ± 24.2 < 0.001
∆ LVEF (absolute %) 3.5 ± 6.2 10.9 ± 9.3 0.013
∆ IVMD (ms) − 35 ± 37 − 37 ± 34 0.832
∆ QRS duration (ms) 3.6 ± 28.0 17.6 ± 28.2 0.132
∆ Peak VO2 (ml/kg/min) 2.2 ± 2.9 1.36 ± 3.5 0.615
∆ Predicted peak VO2 
(absolute %)
12.4 ± 15.1 6.7 ± 16.0 0.365
∆ VE/VCO2 slope 10 (19) 3 (6) 0.049
∆ BNP (pmol/L) − 14 (360) 32 (106) 0.627
∆ Creatinine (µmol/L) 5.0 (29) − 1.5 (22) 0.159
NYHA improvement (%) 6 (60) 50 (66) 0.718
∆ indicates a change, BNP brain natriuretic peptide, ICM ischaemic 
cardiomyopathy, IVMD interventricular mechanical delay, LVEF 
left ventricular ejection fraction, LVESV left ventricular end-systolic 
volume, MACE major adverse cardiac events, NYHA New York Heart 
Association, NICM non-ischaemic cardiomyopathy, VO2 oxygen 
consumption, VE/VCO2 CO2 exchange efficiency.
Table 5 Comparison of changes in echocardiographic, cardiopulmo-
nary, and laboratory parameters between patients with ischaemic car-








∆ LVESV (%) − 12.7 ± 20.5 − 16.8 ± 19.8 0.392
∆ LVEF (absolute %) 3.5 ± 6.3 5.5 ± 7.8 0.269
∆ IVMD (ms) − 26 ± 35 − 31 ± 31 0.537
∆ QRS duration (ms) 4.3 ± 29.3 15.1 ± 24.3 0.101
∆ Peak VO2 (ml/kg/min) 0.1 ± 2.8 0.8 ± 2.5 0.299
∆ Predicted peak VO2 
(absolute %)
2.7 ± 13.9 5.3 ± 13.6 0.496
∆ VE/VCO2 slope 0.7 (18) 4.4 (13) 0.139
∆ BNP (pmol/L) 35 (77) − 53 (78) 0.041
∆ Creatinine (µmol/L) − 6.0 (27) − 5.0 (22) 0.673
NYHA improvement (%) 6 (27) 44 (60) 0.008
∆ indicates a change, BNP brain natriuretic peptide, ICM ischaemic 
cardiomyopathy, IVMD interventricular mechanical delay, LVEF 
left ventricular ejection fraction, LVESV left ventricular end-
systolic volume, MACE major adverse cardiac events, NYHA New 
York Heart Association, NICM non-ischaemic cardiomyopathy, VO2 
oxygen consumption, VE/VCO2 CO2 exchange efficiency.
KEY MESSAGE  ∆ LVESV is not a suitable surrogate marker for patients with ischemic cardiomyopathy   
The solid curve represents the total population showing a moderate area under the curve. When the population
is stratified according to aetiology of heart failure it is shown that for non-ischaemic patients   LVESV shows
excellent prognostic value concerning the ‘true endpoint’. However, for ischaemic patients   LVESV shows very
poor prognostic value concerning the ‘true endpoint’ 
Figure 2
Area under the receiver-operating curve for left ventricular end-systolic volume decrease
(%) and its association with major adverse cardiac events in the total study cohort, non-
ischaemic, and ischaemic subpopulation. 
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ing modality applied. This could also be true for assessment 
of response. This should be investigated in future research.
Conclusion
∆LVESV is the most reliable surrogate marker for CRT 
response in the total population. This is attributed to the 
non-ischaemic cardiomyopathy subpopulation in which 
∆LVESV showed an excellent correlation with long-term 
outcome. On the other hand, for ischaemic cardiomyopa-
thy ∆LVESV showed a poor correlation with long-term 
outcome. Therefore cardiologists should be careful using 
volumetric response as a prognostic marker in ischaemic 
cardiomyopathy.
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